Answers are grounded in this paper and cite their sources.
Introduction Nanoparticle aggregation assays read out by bulk optical measurement are limited in sensitivity because, at low analyte concentrations, only a small fraction of particles associate. As a methodological proof of concept, we asked whether the epitope that a capture antibody recognises on a multivalent analyte governs the performance of gold nanoparticle (AuNP) aggregation assays read out by nanoparticle tracking analysis (NTA). Human immunoglobulin G (IgG) was used purely as a bivalent model scaffold, not as a clinical target. Methods AuNPs were functionalised through a streptavidin bridge with biotinylated antibodies against either the Fab or the Fc region of IgG, and the two probes were tested individually and as a one-to-one mixture across 19.9–199.4 fg/mL (0.13–1.33 fM) of antigen, with association followed by ultraviolet–visible (UV–Vis) spectroscopy and by NTA. Results Both methods ranked the three formats identically. The Fab-targeted probe was the only format with a monotonic, linear response (R 2 = 0.953), giving an NTA limit of detection of 65.1 fg/mL (0.43 fM) within a 35-minute assay, approximately 6.7 × 104-fold below its UV–Vis limit (4.33 ng/mL). Discussion Because the calibrated range spans one order of magnitude and the limit of quantification (197 fg/mL; 1.31 fM) lies at its upper end, the assay is best regarded as detecting and semi-quantitatively ranking antigen rather than quantifying it. The mixed probe gave the largest signal but a stepwise response suited to qualitative screening. The Fc-targeted probe did not titrate; because this preparation was already partially aggregated before antigen addition, its failure cannot be attributed to epitope choice alone. Antibody-free and non-target-antigen controls remained at baseline, but the magnitude of the NTA response exceeds what one-to-one antigen bridging of particles could produce, so the aggregation index is treated as an empirical, antigen-specific indicator whose amplification mechanism remains to be resolved. All measurements were made in dilute buffer, so matrix tolerance was not tested. Validation in serum, comparison with a reference immunoassay, and extension to genuinely low-abundance multivalent biomarkers are required before any diagnostic use is considered.
No takes yet. Share an insight, caveat, or question.
Sah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: